Polskie Towarzystwo
Hematologów i Transfuzjologów

czcionka: [+] powiększ | [-] pomniejsz

Acta Haematologica Polonica, 2011, 42, 2

IRENA FRYDECKA · AGATA KOSMACZEWSKA · LIDIA CISZAK · ANNA MASTERNAK · DARIUSZ WOSZCZYK

A blockade of the inhibitory CTLA-4 molecule – a novel strategy for the immunotherapy of neoplastic diseases

Blokada inhibitorowej cząsteczki CTLA-4 – nowa metoda immunoterapii schorzeń nowotworowych

SłOWA KLUCZOWE:
CTLA-4 blockadeImmunotherapyMalignancyIpilimumabTremelimumab.
KEY WORDS:
-
pełna treść »
STRESZCZENIE: Cytotoxic T lymphocyte antigen 4 (CTLA-4) is a key negative regulator of T cell responses influencing the antitumor
immunity. Ipilimumab (MDX-010, Medarex, Inc. and Bristol-Myers Squibb) and tremelimumab (CP-675,206, Pfizer
Pharmaceuticals) are fully human monoclonal antibodies that block interaction CTLA-4/B7 ligands on APC, thus
leading to the tumor tolerance breakdown. Preclinical and clinical studies of patients with malignancies show that
CTLA-4 blockade promotes antitumor immunity as monotherapy or in combination with other strategies, including
chemotherapy, vaccine, and cytokines. A novel kinetic pattern of the clinical response has been observed after anti-
CTLA-4 Abs infusion with delayed tumor regression following the early short-term disease progression. Our understanding
about management of the patients treated with CTLA-4 blockade is also recently increased by the notion of
severe immune-related adverse events (IAEs) association with good clinical response. In some patients with advanced
malignancies, durable disease stabilization or symptomatic improvements may be potentially beneficial outcome, as
well. This work briefly reviews the results from completed clinical trials of CTLA-4 blockade in solid tumors as well
as hematological malignancies, suggesting its usefulness as a novel strategy for the immunotherapy.
SUMMARY: -

pełna treść:

pobierzpobierz pełną treść publikacji (PDF 124kb)

Pobierz program Adobe Reader®Do otwarcia plików PDF niezbedny jest darmowy program Adobe Reader® Jeśli nie masz tego programu pobierz go tutaj